Benzo[c]quinolizin-11-ium

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: Benzo[c]quinolizin-11-ium
• 化学式: C13H10N+
• 分子量: 180.22
• InChiKey: WNRBERXEBGAUGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  4.1
• 氢给体数：
  0
• 氢受体数：
  0

文献信息

• Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：US20160095858A1

  公开（公告）日：2016-04-07

  The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

  本发明涉及一种具有以下化学式I的化合物： 或其药用可接受的盐，其中R 1 ，R 2 ，R 3 ，W，X，Y，Z，n，o，p和q在此处定义，用于治疗CFTR介导的疾病，如囊性纤维化。本发明还涉及药物组合物、治疗方法和相关工具包。
• [EN] MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR<br/>[FR] MODULATEURS DU RÉGULATEUR DE LA CONDUCTANCE TRANSMEMBRANAIRE DE LA FIBROSE KYSTIQUE
  申请人：VERTEX PHARMA

  公开号：WO2017173274A1

  公开（公告）日：2017-10-05

  The present disclosure features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, W, X, Z, n, p, and Rings A and B are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present disclosure also features pharmaceutical compositions, method of treating, and kits thereof.

  本公开涉及一种具有化学式I的化合物：或其药用可接受的盐，其中R1、R2、W、X、Z、n、p以及环A和环B在此处被定义，用于治疗CFTR介导的疾病，如囊性纤维化。本公开还涉及药物组合物、治疗方法以及相关工具包。
• [EN] PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES<br/>[FR] COMPOSITIONS PHARMACEUTIQUES POUR LE TRAITEMENT DE MALADIES MÉDIÉES PAR CFTR
  申请人：VERTEX PHARMA

  公开号：WO2014071122A1

  公开（公告）日：2014-05-08

  Pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5- yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4- oxo-1H-quinoline-3-carboxamide (Compound 2), methods of treating, lessening the severity of, or symptomatically treating CFTR mediated diseases, such as cystic fibrosis, methods of manufacturing, methods of administering, and kits thereof are disclosed.

  含有3-(6-(1-(2,2-二氟苯并[d][1,3]二氧杂环戊-5-基)环丙基羧胺基)-3-甲基吡啶-2-基)苯甲酸（化合物1）的制药组合物，形式I和包含基本无定形N-(5-羟基-2,4-二叔丁基苯基)-4-氧代-1H-喹啉-3-羧酰胺（化合物2）的固体分散体，用于治疗、减轻或症状性治疗CFTR介导的疾病，如囊性纤维化，公开了制造方法、给药方法和相关的试剂盒。
• Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US10980746B2

  公开（公告）日：2021-04-20

  The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.

  本发明涉及包含多种治疗剂的组合物，其中一种治疗剂的存在增强了至少一种其他治疗剂的性能。在一个实施例中，治疗剂是囊性纤维化跨膜传导调节蛋白（CFTR），例如CFTR校正剂或CFTR增强剂，用于治疗CFTR介导的疾病，如囊性纤维化。还公开了相关的方法和试剂盒。
• MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS
  申请人：HADIDA RUAH SARA S.

  公开号：US20090143381A1

  公开（公告）日：2009-06-04

  Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

  本发明的化合物及其药用可接受的组合物可用作ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜传导调节蛋白（“CFTR”）。本发明还涉及使用本发明的化合物治疗ABC转运蛋白介导的疾病的方法。